Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Have completed the core CZOL446H2202 study

• Males or females between 1-17 years of age

Exclusion Criteria:

• Deformity or abnormality which would prevent spine bone density from being done

• Any surgical bone-lengthening procedure

• Any kidney diseases or abnormalities

• Low calcium or vitamin D levels in the blood

Other protocol-defined inclusion/exclusion criteria may apply.